Influence of Thymoglobuline on Phenotypic and Functional Profiles of B Lymphocytes in Renal Transplant Recipients

The investigators expect to better characterise B cell subpopulation and functional properties early after graft, to analyse effect of induction therapy (thymoglobulin versus basiliximab) on B cells, and to compare this B cell profiles with those obtained in our previous study in patients with chronic Antibody Mediated Rejection (cAMR)

Completed

Looking for future studies?

Notify Me

Key information

Conditions

Renal Transplant

Age range

18 year and older

Sex eligibility

All sexes

Study type

Observational

Primary location

CHU Brest, Brest, France

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

Age >18 years old
Recipient of a renal allograft
Patient receiving either basiliximab or thymoglobulin as in induction therapy for renal transplant
Patient presenting a low immunologic risk
Patient not opposed to his (her) study participation

Exclusion criteria

Patient participating in a clinical trial

Treatment and study plan

Thymoglobulin Induction

Drug

The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Thymoglobulin treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.

Basiliximab Induction

Drug

The choice of the induction therapy is not a procedure of the study. This choice is made by the practioner, based on the graft recipient profile. This is a predefined group, the Basiliximab treatment is not an intervention in the study but must be considered as an exposure that is defined before the patient enters the study.

Primary outcomes

The distribution of mature blood B cells subpopulations will be compared between the 2 groups

Time frame: one year after renal transplant
Proliferation of freshly isolated cells T in presence of autologous B cells will be compared between the 2 groups.

Time frame: one year after renal transplant

Secondary outcomes

Serum B-cell activating factor (BAFF) concentration comparison between the two groups

Time frame: one year after renal transplant

Sponsors and collaborators

Lead sponsor

University Hospital, Brest

Other

Registry information

Acronym: THYMO B

Important dates

Study start: 2015
Primary completion: 2018
Study completion: 2018
First posted: Sep 9, 2016
Registry last updated: Jun 8, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.

Completed